Breaking News, Collaborations & Alliances

DelMar Collaborates with PRA Health Sciences

CRO will conduct for phase 3 trial of VAL-083 in recurrent glioblastoma multiforme

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DelMar Pharmaceuticals, a biopharmaceutical company focused on developing new cancer therapies, has formed an agreement with PRA Health Sciences, a contract research organization (CRO), to conduct the company’s Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM). “We have been working with PRA for quite some time in preparing for VAL-083’s Phase 3 study in GBM,” said Jeffrey Bacha, chairman and chief executive officer, DelMar Pharmaceuticals. “Giv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters